Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting

Core Insights - Upstream Bio, Inc. presented additional data from the Phase 2 VIBRANT clinical trial for verekitug, showing significant efficacy in treating chronic rhinosinusitis with nasal polyps (CRSwNP) [1][2] - The trial demonstrated a placebo-adjusted reduction in endoscopic nasal polyp score (NPS) of -1.95 (p < 0.0001) and a reduction in nasal congestion score (NCS) of -0.96 (p < 0.0001) [1][2] - The company plans to initiate Phase 3 trials for CRSwNP and severe asthma, highlighting verekitug's potential to improve treatment standards for serious respiratory diseases [2][3] Company Overview - Upstream Bio is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders [11] - Verekitug is a novel monoclonal antibody targeting the thymic stromal lymphopoietin (TSLP) receptor, which plays a key role in inflammatory responses [8][11] - The company aims to address unmet needs in patients with conditions like CRSwNP and severe asthma through innovative therapies [11] Clinical Trial Details - The VIBRANT trial was a global, randomized, double-blind, placebo-controlled study involving 81 adults with CRSwNP, assessing the efficacy and safety of verekitug over 24 weeks [7] - Participants received 100 mg of verekitug or placebo every 12 weeks, with primary and secondary endpoints focused on nasal polyp scores and other symptoms [7] - The trial's design and endpoints are intended to support future regulatory submissions for product approval [3][7] Efficacy and Safety - Verekitug reduced the need for surgery or systemic corticosteroids by 76% (p = 0.03) compared to placebo, indicating a strong therapeutic effect [1][2] - The treatment was generally well tolerated, with no serious adverse events (SAEs) reported, reinforcing its favorable safety profile [1][2] Future Directions - Upstream Bio is preparing to initiate registrational trials for verekitug in CRSwNP and severe asthma, following planned interactions with regulatory authorities [3] - The company believes verekitug's unique mechanism of action and dosing schedule could significantly enhance the standard of care for patients with serious respiratory diseases [2]